The
The cancer drug developer posted revenue of
Actinium shares have dropped 9% since the beginning of the year. In the final minutes of trading on Friday, shares hit
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
Copyright by Automated Insights, Inc. All rights reserved., source